Cargando…

A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome

INTRODUCTION: Chronic pain and fatigue are the main symptoms of postpoliomyelitis syndrome (PPS). This study aimed to evaluate the efficacy and safety of an anthroposophic multimodal treatment for chronic pain in PPS outpatients. METHODS: A twelve‐week, four‐arm, randomized, double‐blind, placebo‐co...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghelman, Ricardo, Akiyama, Ivete Y., de Souza, Valeria T., Falcão, Jussara, Orgolini, Vera, Hosomi, Jorge K., Quadros, Abrahão A. J., Oliveira, Acary S. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177555/
https://www.ncbi.nlm.nih.gov/pubmed/32162497
http://dx.doi.org/10.1002/brb3.1590
_version_ 1783525246005936128
author Ghelman, Ricardo
Akiyama, Ivete Y.
de Souza, Valeria T.
Falcão, Jussara
Orgolini, Vera
Hosomi, Jorge K.
Quadros, Abrahão A. J.
Oliveira, Acary S. B.
author_facet Ghelman, Ricardo
Akiyama, Ivete Y.
de Souza, Valeria T.
Falcão, Jussara
Orgolini, Vera
Hosomi, Jorge K.
Quadros, Abrahão A. J.
Oliveira, Acary S. B.
author_sort Ghelman, Ricardo
collection PubMed
description INTRODUCTION: Chronic pain and fatigue are the main symptoms of postpoliomyelitis syndrome (PPS). This study aimed to evaluate the efficacy and safety of an anthroposophic multimodal treatment for chronic pain in PPS outpatients. METHODS: A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial was designed to compare four groups (n = 48): groups A and B received daily active experimental transdermal gel (ETG) or placebo gel (PTG), respectively; groups C and D received weekly external therapies, art therapies, and neurofunctional reorganization, plus either daily ETG or PTG, respectively. The pain symptoms were evaluated through a visual analogue scale (VAS), the McGill questionnaire, and thermography. Quality of life and resilience were evaluated by the WHOQOL‐BREF and Antonovsky sense of coherence questionnaires applied at baseline and after the interventions. RESULTS: No related adverse events occurred, and 10% of the patients reports dysphagia improvement. In the groups C and D, pain reduction was statistically significant in both the placebo group (p = .02, d = 1.315) and in the ETG (p = .005, d = 2.035). However, following the week‐to‐week evolution of pain with the concomitant use of the ETG, this significant pain reduction occurred earlier from the 4th week and continued to decrease (p = .016, d = 1.369). In the group that received the complete multimodal treatment, the greatest significant benefit in increasing quality of life occurred in the physical domain and elevation in resilience with an emphasis on meaning and comprehension domains. CONCLUSIONS: The anthroposophic multimodal treatment group presented both safety and efficacy as an analgesic in the groups that received the nonpharmacological therapies, much earlier when associated with the ETG. The multimodal approach corresponded to the pattern of better efficacy for both pain reduction and improvement in quality of life and resilience.
format Online
Article
Text
id pubmed-7177555
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71775552020-04-24 A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome Ghelman, Ricardo Akiyama, Ivete Y. de Souza, Valeria T. Falcão, Jussara Orgolini, Vera Hosomi, Jorge K. Quadros, Abrahão A. J. Oliveira, Acary S. B. Brain Behav Original Research INTRODUCTION: Chronic pain and fatigue are the main symptoms of postpoliomyelitis syndrome (PPS). This study aimed to evaluate the efficacy and safety of an anthroposophic multimodal treatment for chronic pain in PPS outpatients. METHODS: A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial was designed to compare four groups (n = 48): groups A and B received daily active experimental transdermal gel (ETG) or placebo gel (PTG), respectively; groups C and D received weekly external therapies, art therapies, and neurofunctional reorganization, plus either daily ETG or PTG, respectively. The pain symptoms were evaluated through a visual analogue scale (VAS), the McGill questionnaire, and thermography. Quality of life and resilience were evaluated by the WHOQOL‐BREF and Antonovsky sense of coherence questionnaires applied at baseline and after the interventions. RESULTS: No related adverse events occurred, and 10% of the patients reports dysphagia improvement. In the groups C and D, pain reduction was statistically significant in both the placebo group (p = .02, d = 1.315) and in the ETG (p = .005, d = 2.035). However, following the week‐to‐week evolution of pain with the concomitant use of the ETG, this significant pain reduction occurred earlier from the 4th week and continued to decrease (p = .016, d = 1.369). In the group that received the complete multimodal treatment, the greatest significant benefit in increasing quality of life occurred in the physical domain and elevation in resilience with an emphasis on meaning and comprehension domains. CONCLUSIONS: The anthroposophic multimodal treatment group presented both safety and efficacy as an analgesic in the groups that received the nonpharmacological therapies, much earlier when associated with the ETG. The multimodal approach corresponded to the pattern of better efficacy for both pain reduction and improvement in quality of life and resilience. John Wiley and Sons Inc. 2020-03-11 /pmc/articles/PMC7177555/ /pubmed/32162497 http://dx.doi.org/10.1002/brb3.1590 Text en © 2020 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Ghelman, Ricardo
Akiyama, Ivete Y.
de Souza, Valeria T.
Falcão, Jussara
Orgolini, Vera
Hosomi, Jorge K.
Quadros, Abrahão A. J.
Oliveira, Acary S. B.
A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome
title A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome
title_full A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome
title_fullStr A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome
title_full_unstemmed A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome
title_short A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome
title_sort twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177555/
https://www.ncbi.nlm.nih.gov/pubmed/32162497
http://dx.doi.org/10.1002/brb3.1590
work_keys_str_mv AT ghelmanricardo atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT akiyamaivetey atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT desouzavaleriat atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT falcaojussara atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT orgolinivera atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT hosomijorgek atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT quadrosabrahaoaj atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT oliveiraacarysb atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT ghelmanricardo twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT akiyamaivetey twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT desouzavaleriat twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT falcaojussara twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT orgolinivera twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT hosomijorgek twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT quadrosabrahaoaj twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome
AT oliveiraacarysb twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome